Valeant's Battle for Allergan
Case number:
A06-18-0005
Abstract
On April 21, 2014 two companies, Valeant Pharmaceuticals and Pershing Square, announced an unsolicited merger offer for Allergan Pharmaceuticals. The unsolicited offer quickly turned into a hostile acquisition. The following months saw a raging public debate over the future control of Allergan and its primary product, Botox, as well as the business strategies and philosophies of the two offering firms and their CEOs.
Teaching
This case has been used in both graduate business and management degree and non-degree programs to provide a platform for discussions of a number of differing issues, including mergers and acquisitions, corporate governance and control, activist investing, organic versus acquisition-based growth, and the mechanics of friendly and hostile acquisitions.
Case number:
A06-18-0005
Subject:
Finance
Year:
Setting:
USA
Length:
18
Source:
Library